12 febrero 2014

Key RNAi Drugs in the Clinic .

February 06, 2014 .

Having had over a decade to mature, the RNAi drugs industry has more therapeutic candidates in clinical development than ever, testing in humans agents that incorporate a variety of designs, modifications, and delivery strategies.

Below is a list of the key RNAi-based therapies currently under active development, broken down by their developer.

...

Sylentis

SYL040012 — This drug is an unmodified 21-mer designed to silence adrenergic receptor beta-2 as a way to treat the ocular hypertension and elevated intraocular pressure associated with open-angle glaucoma.

Administered as eye drops, the drug has been tested in three clinical trials thus far, including a recently completed phase II trial. A phase IIb study is planned for this year.

SYL1001 — Like Sylentis' other drug, SYL1001 is an unmodified siRNA that is delivered topically to the eye. It targets transient receptor potential cation channel subfamily V member 1, which plays a role in pain sensitivity, for ocular pain.

The agent is currently under phase I/II testing for dry eye syndrome.



...